StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Seattle Genetics (SGEN) & Astellas Update Phase 1 Data of Investigational Antibody-Drug Conjugate Enfortumab Vedotin
June 4, 2018 6:37 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. today announced the presentation of updated phase 1 data of enfortumab ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
June 3, 2018 9:00 AM